Global EditionASIA 中文双语Français
Business
Home / Business / Industries

Experts predict China's bioinnovation sector to be among world's best

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2020-11-16 15:32
Share
Share - WeChat
Experts from academic research, biotechnology, and venture capital fields discuss the prospects and challenges of basic research in China's pharmaceutical healthcare sectors at a recent seminar held by Servier BioInnovation Asia in Shanghai. [Photo provided to chinadaily.com.cn]

China's bioinnovation industry is undergoing a process of gradual upgrade and will be among the world's foremost in the upcoming years, experts said during a recent seminar discussing the prospects and challenges of basic research in China's pharmaceutical healthcare sectors in Shanghai.

Such an upgrade will be possible through not only technological breakthroughs but also other factors such as market, policy, capital and an ecosystem of pharmaceutical innovation that would need to be established by such parties, said experts from academic research, biotechnology, and venture capital fields at the seminar held by Servier BioInnovation Asia.

The government has been paying increasing attention to innovation in basic pharmaceutical healthcare research, and has continuously introduced new policies in this realm, said Liao Maijing, chief business officer of Harbour BioMed (Shanghai) Co Ltd.

Through more early-phase collaborations with academic institutions and hospitals, domestic companies with independent and innovative technologies are aiming to turn more research results into products at a faster pace, broaden their portfolios, and realize business growth with more external cooperation, said Liao.

"Through active collaborative deals, initial public offerings (IPOs) in China and globally, and more capital support, the country's biomedical innovation is gradually forming a positive development ecosystem with policy support, capital availability, and mature models," said Wang Yueyue, managing partner of T-Capital.

Didier Landais, global head of Licensing and Managing Director of Servier BioInnovation, said that the Servier Group is implementing and expanding its bioinnovation network to access the best opportunities for research collaboration, licensing agreements and acquisitions with the world's leading biomedical and life sciences innovation players.

Stephane Mascarau, general manager of Servier China, said, "We look forward to collaborating with the best Chinese biotech innovators to promote the translation of biomedical technologies and clinical research capabilities, and provide better healthcare to Chinese patients."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE